Story thread · 2 reports / 1 sources
ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation ADCs for Liver Cancer
thehindu.com · 10d
Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India.
First report: ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) Program — thehindu.com, 11d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.